MISSION Therapeutics
Cambridge
About MISSION Therapeutics
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $193.7M
- Last round: Series Unknown (Oct 2025)
- Website: missiontherapeutics.com
- Phone: +44 (0)1223 607 340
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mission-therapeutics-66000 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.